Cresco Labs, LLC

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Cresco Labs, LLC - overview

Established

2013

Location

Chicago, IL, US

Primary Industry

Healthcare

About

Cresco Labs, LLC is a leading cannabis company focused on producing and distributing high-quality cannabis products tailored to various consumer needs, including medical and recreational markets. Founded in 2013 by Charlie Bachtell, Firas Baidoun, Kayvan Khalatbari, and Stephen Ashekian, Cresco Labs is headquartered in Chicago, US. The company has successfully executed two deals, with the most recent transaction being a Series D funding round of USD 100. 00 mn in October 2018, aimed at expanding their operations and product offerings.


Cresco Labs specializes in the production and distribution of a diverse range of cannabis products including premium cannabis flowers, pre-rolls, concentrates, and edibles. Their offerings are designed to cater to both cannabis connoisseurs and medical patients, providing products that address various recreational and therapeutic needs. Cresco Labs operates in strategic markets across the United States such as Illinois, Pennsylvania, and California, distributing their products through both wholesale channels and their own retail locations. Cresco Labs generates revenue through wholesale partnerships with retailers and direct sales at their retail sites.


Their business model encompasses both Business-to-Business (B2B) transactions with wholesalers, who sell products like Cresco and Remedi to end consumers, and direct-to-consumer sales, thereby reaching a wide customer base. Established pricing plans support their revenue structure, although specific pricing details are not disclosed, and they engage in strategic partnerships to enhance distribution and market reach. Cresco Labs plans to utilize its Series D funding of USD 100. 00 mn to expand its footprint in producing and distributing its full suite of medically-focused and adult-use cannabis products.


The company is looking to enhance brand offerings and enter new geographical markets, although specific locations and timelines for expansion have not been disclosed. Their strategy includes the development and launch of new products designed to meet evolving consumer needs.


Primary Industry

Healthcare

Sub Industries

Retail, Alternative Medicine, Pharmaceutical Research & Development

Website

www.crescolabs.com

Verticals

Cannabis/Medical Marijuana, Manufacturing

Company Stage

Series D/Round 4

Total Amount Raised

Subscriber access only

Cresco Labs, LLC - deals

Deals TypeDeal StatusTarget (s)Deal DateInvestor(s)Seller(s)Deal size (Mn)Enterprise value (Mn)Post-money valuation (Mn)EBITDA multiple (x)Revenue multiple (x)Lead partner (s)
Trade SaleCompletedColumbia Care Inc.-
Add-onCompletedLaurel Harvest Labs, LLC-
Add-onAnnouncedBay, LLC-
Add-onCompletedCultivate Holdings, LLC Group-
Add-onCompletedBluma Wellness Inc.-

Displaying 1 - 5 of 8

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.